19 May 2013
Keywords: update, alizyme, takeda, million, obesity, drug, development
Article | 18 August 2003
The UK's Alizyme has granted Japanese licensing and development rights for its promising obesity product candidate ATL-962 to Japan's Takeda
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
18 August 2003
17 May 2013
© 2013 thepharmaletter.com